Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 3
  • Print publication year: 2010
  • Online publication date: December 2010

Chapter 4 - Approach and evaluation of neurogenic bladder dysfunction

from Section 2 - Evaluation and management

References

1. de Groat WC, Booth AM. Physiology of the urinary bladder and urethra. Ann Intern Med 1980;92(Pt 2):312–5.
2. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9:453–66.
3. Fowler CJ. Integrated control of lower urinary tract – clinical perspective. Br J Pharmacol 2006;147(Suppl 2):S14–S24.
4. Norris JP, Staskin DR. History, physical examination, and classification of neurogenic voiding dysfunction. Urol Clin North Am 1996;23:337–43.
5. Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009;56:81–8.
6. Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia 1990;28:217–29.
7. Ahlberg J, Edlund C, Wikkelso C, Rosengren L, Fall M. Neurological signs are common in patients with urodynamically verified “idiopathic” bladder overactivity. Neurourol Urodyn 2002;21(1):65–70.
8. Haab F, Richard F, Amarenco G, et al. Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the Urinary Symptom Profile (USP) questionnaire. Urology 2008;71:646–56.
9. Andersson KE. The overactive bladder: pharmacologic basis of drug treatment. Urology 1997;50(6A Suppl):74–84.
10. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–78.
11. Van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int 2002;90(Suppl 3):11–15.
12. Weiss JP. Nocturia: “do the math”. J Urol 2006;175(3 Pt 2):S16–S18.
13. Beck RP, Arnusch D, King C. Results in treating 210 patients with detrusor overactivity incontinence of urine. Am J Obstet Gynecol 1976;125:593–6.
14. Barry MJ, Fowler FJ, Jr., O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549–57.
15. Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 1995;14:131–9.
16. Shumaker SA, Wyman JF, Uebersax JS, McClish D, Fantl JA. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res 1994;3:291–306.
17. Schurch B, Denys P, Kozma CM, et al. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil 2007;88:646–52.
18. Lubeck DP, Prebil LA, Peeples P, Brown JS. A health related quality of life measure for use in patients with urge urinary incontinence: a validation study. Qual Life Res 1999;8:337–44.
19. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563–74.
20. Costa P, Perrouin-Verbe B, Colvez A, et al. Quality of life in spinal cord injury patients with urinary difficulties. Development and validation of qualiveen. Eur Urol 2001;39:107–13.
21. Bonniaud V, Bryant D, Parratte B, Gallien P, Guyatt G. Qualiveen: a urinary disorder-specific instrument for use in clinical trials in multiple sclerosis. Arch Phys Med Rehabil 2006;87:1661–3.
22. Bonniaud V, Bryant D, Parratte B, Guyatt G. Development and validation of the short form of a urinary quality of life questionnaire: SF-Qualiveen. J Urol 2008;180:2592–8.
23. Acquadro C, Kopp Z, Coyne KS, et al. Translating overactive bladder questionnaires in 14 languages. Urology 2006;67:536–40.
24. Donovan J, Bosch R, Gotoh M, et al. Symptom and quality of life assessment. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Jersey: Health Publications Ltd; 2005.
25. Homma Y, Ando T, Yoshida M, et al. Voiding and incontinence frequencies: variability of diary data and required diary length. Neurourol Urodyn 2002;21:204–9.
26. Wyman JF, Choi SC, Harkins SW, Wilson MS, Fantl JA. The urinary diary in evaluation of incontinent women: a test-retest analysis. Obstet Gynecol 1988;71(6 Pt 1):812–17.
27. Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993;56:245–50.
28. Panicker JN, Nagaraja D, Kovoor JM, Nair KP, Subbakrishna DK. Lower urinary tract dysfunction in acute disseminated encephalomyelitis. Mult Scler 2009;15:1118–22.
29. Staskin DR, Zoltan E. Anticholinergics and central nervous system effects: are we confused? Rev Urol 2007;9:191–6.
30. Royal College of Nursing. Catheter Care. RCN Guidance for Nurses. London: Royal College of Nursing; 2008.
31. Fowlis GA, Waters J, Williams G. The cost effectiveness of combined rapid tests (Multistix) in screening for urinary tract infections. J R Soc Med 1994;87:681–2.
32. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:470–7.
33. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70.
34. Department of Health. National service framework for renal services. Part two: chronic kidney disease, acute renal failure and end of life care. London: Department of Health; 2005.
35. Jenkins MA, Brown DJ, Ierino FL, Ratnaike SI. Cystatin C for estimation of glomerular filtration rate in patients with spinal cord injury. Ann Clin Biochem 2003;40(Pt 4):364–8.
36. Carroll P, Albertsen P, Greene K, et al. Prostate-specific antigen best practice statement: 2009 update. American Urological Association Education and Research, Inc., 2009.
37. Blaivas JG, Appell RA, Fantl JA, et al. Standards of efficacy for evaluation of treatment outcomes in urinary incontinence: recommendations of the Urodynamic Society. Neurourol Urodyn 1997;16:145–7.
38. Fowler CJ, O'Malley KJ. Investigation and management of neurogenic bladder dysfunction. J Neurol Neurosurg Psychiatry 2003;74(Suppl 4):iv27–iv31.
39. Stohrer M, Castro-Diaz D, Chartier-Kastler E, et al. Guidelines on neurogenic lower urinary tract dysfunction. Prog Urol 2007;17:703–55.
40. de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007;13:915–28.
41. Schafer W, Abrams P, Liao L, et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002;21:261–74.
42. Blaivas JG, Groutz A. Bladder outlet obstruction nomogram for women with lower urinary tract symptomatology. Neurourol Urodyn 2000;19:553–64.
43. Abrams P, Agarwal M, Drake M, et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int 2008;101:989–94.
44. Ruffion A, de Seze M, Denys P, Perrouin-Verbe B, Chartier-Kastler E. Groupe d'Etudes de Neuro-Urologie de Langue Francaise (GENULF) guidelines for the management of spinal cord injury and spina bifida patients. Prog Urol 2007;17:631–3.
45. Podnar S, Vodusek DB. Standardization of anal sphincter electromyography: utility of motor unit potential parameters. Muscle Nerve 2001;24:946–51.
46. Podnar S, Trsinar B, Vodusek DB. Bladder dysfunction in patients with cauda equina lesions. Neurourol Urodyn 2006;25:23–31.
47. Fowler CJ, Christmas TJ, Chapple CR, et al. Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome? BMJ 1988;297:1436–8.
48. Podnar S. Nomenclature of the electrophysiologically tested sacral reflexes. Neurourol Urodyn 2006;25:95–7.
49. Lefaucheur JP, Labat JJ, Amarenco G, et al. What is the place of electroneuromyographic studies in the diagnosis and management of pudendal neuralgia related to entrapment syndrome? Neurophysiol Clin 2007;37:223–8.
50. Opsomer RJ, Guerit JM, Wese FX, Van Cangh PJ. Pudendal cortical somatosensory evoked potentials. J Urol 1986;135:1216–8.
51. Cavalcanti GA, Bruschini H, Manzano GM, et al. Pudendal somatosensory evoked potentials in normal women. Int Braz J Urol 2007;33:815–21.
52. Delodovici ML, Fowler CJ. Clinical value of the pudendal somatosensory evoked potential. Electroencephalogr Clin Neurophysiol 1995;96:509–15.
53. Panicker JN, Menon L, Anandkumar A, Sundaram KR, Fowler CJ. Lower urinary tract symptoms following neurological illness may be influenced by multiple factors: observations from a neurorehabilitation service in a developing country. Neurourol Urodyn 2010;29:378–81.
54. Panicker J, de Sèze M, Fowler C. Neurogenic lower urinary tract dysfunction and its management. Clin Rehab. In press.